Summary
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD.
The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Read Complete Report with TOC: http://www.radiantinsights.com/research/pharmapoint-major-depressive-disorder-australia-drug-forecast-and-market-analysis-to-2023
Despite patent expiries for key products, Eli Lilly's Cymbalta in 2013, Otsuka Pharmaceutical/BMS's Abilify in 2016, and AstraZeneca's Seroquel XR in 2017, the MDD market value in Australia is not anticipated to decline, as generic products are priced similarly to branded products and any loss of market value due to potential price discounts is expected to be offset by the increasing prevalent cases of MDD, the launch of Brintellix and the potential introduction of late-stage pipeline products during the forecast period.
Scope
- Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Australia from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Australia Major depressive disorder market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in Australia.
About Us
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD.
The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Read Complete Report with TOC: http://www.radiantinsights.com/research/pharmapoint-major-depressive-disorder-australia-drug-forecast-and-market-analysis-to-2023
Despite patent expiries for key products, Eli Lilly's Cymbalta in 2013, Otsuka Pharmaceutical/BMS's Abilify in 2016, and AstraZeneca's Seroquel XR in 2017, the MDD market value in Australia is not anticipated to decline, as generic products are priced similarly to branded products and any loss of market value due to potential price discounts is expected to be offset by the increasing prevalent cases of MDD, the launch of Brintellix and the potential introduction of late-stage pipeline products during the forecast period.
Scope
- Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Australia from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Australia Major depressive disorder market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2013-2023 in Australia.
About Us
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment